Page 43 - Icahn Mount News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Mount Sinai Department of Surgery Launches Program to Combat Burnout and Manage Stress Among Surgical Faculty, Trainees & Staff Share Article Recognizing that burnout and stress have a negative impact on the personal and professional lives of faculty, staff, and trainees, as well as the quality of care that patients receive, the Mount Sinai Department of Surgery has launched the Stress Intervention Tools (SIT) program to help surgeons work through their emotions, reduce their anxiety, and manage crises. NEW YORK (PRWEB) May 06, 2...

IMAGE: Synergy Scores Mount Sinai Health System A combination of remdesivir, a drug currently approved in the United States for treating COVID-19 patients, and repurposed drugs for hepatitis C virus (HCV) was 10 times more effective at inhibiting SARS-CoV-2, the virus that causes COVID-19. The combination therapy points a way toward a treatment for unvaccinated people who become infected, as well as for vaccinated people whose immunity has waned, for example due to the emergence of virus variants that escape this immune protection. Four HCV drugs--simeprevir, vaniprevir, paritaprevir, and ...

Hospitalized COVID-19 Patients Have Mild Risk of Heart Failure by Angela Mohan on  April 27, 2021 at 5:28 PM Doctors should be aware of this potential complication. The study, published in the Journal of the American College of Cardiology, may suggest more monitoring of heart failure symptoms among patients hospitalized with COVID-19. "This is one of the largest studies to date to specifically capture instances of new heart failure diagnosis among patients hospitalized with COVID-19. While rare, the finding of new heart failure was more common among patients with preexisti...

Effect of COVID-19 Antiviral Remdesivir Multiplied 10-Fold by Hepatitis C Drugs Effect of COVID-19 Antiviral Remdesivir Multiplied 10-Fold by Hepatitis C Drugs Drugs used to treat hepatitis C render remdesivir 10 times better at inhibiting the coronavirus in cell cultures. [Jenna Luecke/University of Texas at Austin] April 27, 2021 Share Remdesivir, the only antiviral drug approved in the United States for treating COVID-19 patients, is up to 10 times more effective when it is mixed with a repurposed hepatitis C drug. The effect has been observed with several hepatitis C drugs—namely, sime...

 E-Mail Patients hospitalized with COVID-19 may be at risk of developing heart failure even if they do not have a previous history of heart disease or cardiovascular risk factors, a new Mount Sinai study shows. Researchers say that while these instances are rare, doctors should be aware of this potential complication. The study, published in the April 26 online issue of the Journal of the American College of Cardiology, may prompt more monitoring of heart failure symptoms among patients hospitalized with COVID-19. "This is one of the largest studies to date to specifically capture instan...